Products under development
Inventprise has improved vaccines in various stages of development. They are designed to be safer, more stable and less expensive. Contact us for more information about specific products.
Multivalent pneumococcal vaccine
We’ve developed a multivalent pneumococcal conjugate vaccine using Inventprise’s improved conjugation technology. We’re also working on a multivalent, polysaccaride vaccine for adults.
Heat-stable Rotavirus vaccineWe’ve developed an innovative low volume (0.5 mL or less) oral rotavirus vaccine formulation which does not require refrigeration, and therefore is more stable, easier to administer, and reduces cold storage, transport and distribution costs. The new vaccine utilizes our patented technology to produce a thermostable formulation. This improves the release of live attenuated rotavirus into the intestine to provide immunity.
Yellow Fever VaccineWe’re developing a next generation inactivated yellow fever vaccine based on cell culture technology. This will eliminate field reactions common with current egg-based vaccines, making the vaccine safer and a more viable option for travelers and other patients, as well as for international health organizations such as UNICEF and PAHO.
Acellular PertussisOur team is developing a novel acellular injectable pertussis vaccine. This involves establishing a method of making antigens, formulation of the end product, and the ability to stabilize the vaccine, allowing us to offer it to a global market.
Hia Vaccine (haemophilus influenza type a)
Hia predominantly affects relatively small populations residing in Arctic territories – that is why there has been little corporate interest in targeting this devastating illness. But Inventprise is concerned about this unmet need and, in collaboration with Inventvacc Biologicals and the National Council of Canada, we are working on the world’s first Hia vaccine.
Inventprise is developing a process for creating carrier proteins for pneumococcal conjugates.
Meningococcal A C Y W135 Vaccine
We are developing a multivalent meningococcal conjugate vaccine including the A, C, Y, and W135 strains of polysaccharide antigens.
Group B Streptococcal VaccineInventprise is working on a cost effective, high yield method of fermentation and purification of six different serotypes of Group B streptococcus for PATH and the Biovac Institute.
This new vaccine will target Hib, hepatitis B, pertussis, polio and tetanus. We are in the early planning stages for this product.